Zevra Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Zevra Therapeutics, Inc. (ZVRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $7.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-03-09
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $7.60M, a 6.17% decline from fiscal 2024.
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $8.10M, a 11.96% decline from fiscal 2023.
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $9.20M, a 206.67% increase from fiscal 2022.
- Zevra Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $3.00M, a 50.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $7.60M 10-K · filed 2026-03-09 | |
| 2024-12-31 | $8.10M 10-K · filed 2026-03-09 | |
| 2023-12-31 | $9.20M 10-K · filed 2025-03-12 | |
| 2022-12-31 | $3.00M 10-K · filed 2024-04-01 | $3.70M 10-K · filed 2023-03-07 |
| 2021-12-31 | $2.00M 10-K · filed 2023-03-07 | |
| 2020-12-31 | $3.70M 10-K · filed 2022-03-31 | |
| 2019-12-31 | $4.90M 10-K · filed 2021-03-12 | |
| 2018-12-31 | $5.90M 10-K · filed 2020-02-28 | |
| 2017-12-31 | $4.10M 10-K · filed 2019-03-01 | |
| 2016-12-31 | $5.40M 10-K · filed 2018-03-30 | |
| 2015-12-31 | $1.10M 10-K · filed 2018-03-30 | |
| 2014-12-31 | $200.00K 10-K · filed 2017-03-10 | |
| 2013-12-31 | $200.00K 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |